News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
332,959 Results
Type
Article (32248)
Company Profile (146)
Press Release (300565)
Multimedia
Podcasts (23)
Webinars (3)
Section
Business (87645)
Career Advice (415)
Deals (13838)
Drug Delivery (46)
Drug Development (50474)
Employer Resources (53)
FDA (7024)
Job Trends (7254)
News (157485)
Policy (12774)
Tag
Academia (2131)
Academic (1)
Accelerated approval (4)
Adcomms (17)
Allergies (25)
Alliances (26158)
ALS (58)
Alzheimer's disease (922)
Antibody-drug conjugate (ADC) (151)
Approvals (7045)
Artificial intelligence (162)
Autoimmune disease (11)
Automation (8)
Bankruptcy (104)
Best Places to Work (6021)
BIOSECURE Act (15)
Biosimilars (49)
Biotechnology (114)
Bladder cancer (87)
Brain cancer (30)
Breast cancer (324)
Cancer (2486)
Cardiovascular disease (61)
Career advice (383)
Career pathing (9)
CAR-T (152)
Cell therapy (347)
Cervical cancer (22)
Clinical research (40140)
Collaboration (546)
Company closure (2)
Compensation (221)
Complete response letters (13)
COVID-19 (1404)
CRISPR (27)
C-suite (139)
Cystic fibrosis (39)
Data (1484)
Decentralized trials (1)
Denatured (2)
Depression (15)
Diabetes (85)
Diagnostics (4060)
Digital health (6)
Diversity (4)
Diversity, equity & inclusion (15)
Drug discovery (73)
Drug pricing (46)
Drug shortages (4)
Duchenne muscular dystrophy (30)
Earnings (28820)
Editorial (16)
Employer branding (10)
Employer resources (48)
Events (52765)
Executive appointments (362)
FDA (7735)
Friedreich's ataxia (2)
Frontotemporal dementia (6)
Funding (485)
Gene editing (50)
Generative AI (9)
Gene therapy (163)
GLP-1 (259)
Government (1988)
Guidances (74)
Healthcare (9915)
Huntington's disease (11)
IgA nephropathy (5)
Immunology and inflammation (63)
Indications (20)
Infectious disease (1461)
Inflammatory bowel disease (70)
Inflation Reduction Act (5)
Influenza (17)
Intellectual property (47)
Interviews (57)
IPO (7341)
IRA (23)
Job creations (1506)
Job search strategy (339)
Kidney cancer (11)
Labor market (12)
Layoffs (223)
Leadership (3)
Legal (2196)
Liver cancer (81)
Lung cancer (355)
Lymphoma (156)
Machine learning (6)
Management (16)
Manufacturing (138)
MASH (37)
Medical device (4238)
Medtech (4239)
Mergers & acquisitions (6801)
Metabolic disorders (213)
Multiple sclerosis (35)
NASH (5)
Neurodegenerative disease (66)
Neuropsychiatric disorders (13)
Neuroscience (1280)
NextGen: Class of 2025 (2995)
Non-profit (2847)
Now hiring (8)
Obesity (93)
Opinion (105)
Ovarian cancer (85)
Pain (33)
Pancreatic cancer (90)
Parkinson's disease (170)
Partnered (12)
Patents (111)
Patient recruitment (77)
Peanut (11)
People (27794)
Pharmaceutical (30)
Pharmacy benefit managers (5)
Phase I (14303)
Phase II (17690)
Phase III (12235)
Pipeline (838)
Policy (76)
Postmarket research (1394)
Preclinical (6292)
Press Release (32)
Prostate cancer (115)
Psychedelics (13)
Radiopharmaceuticals (241)
Rare diseases (177)
Real estate (2829)
Recruiting (20)
Regulatory (9736)
Reports (18)
Research institute (2122)
Resumes & cover letters (35)
Rett syndrome (2)
RNA editing (3)
RSV (16)
Schizophrenia (39)
Series A (73)
Series B (45)
Service/supplier (1)
Sickle cell disease (34)
Special edition (4)
Spinal muscular atrophy (70)
Sponsored (15)
Startups (1988)
State (1)
Stomach cancer (16)
Supply chain (22)
Tariffs (15)
The Weekly (21)
Vaccines (360)
Venture capitalists (19)
Weight loss (43)
Women's health (18)
Worklife (6)
Date
Today (75)
Last 7 days (463)
Last 30 days (1873)
Last 365 days (17247)
2025 (6584)
2024 (18822)
2023 (21387)
2022 (27519)
2021 (29183)
2020 (26542)
2019 (22297)
2018 (16698)
2017 (16532)
2016 (15912)
2015 (18688)
2014 (14011)
2013 (11400)
2012 (11846)
2011 (12207)
2010 (11251)
Location
Africa (317)
Alabama (38)
Alaska (5)
Arizona (90)
Arkansas (5)
Asia (22141)
Australia (4221)
California (3404)
Canada (968)
China (378)
Colorado (134)
Connecticut (156)
Delaware (112)
Europe (46324)
Florida (496)
Georgia (95)
Idaho (22)
Illinois (342)
India (15)
Indiana (149)
Iowa (7)
Japan (95)
Kansas (53)
Kentucky (18)
Louisiana (3)
Maine (15)
Maryland (490)
Massachusetts (2367)
Michigan (52)
Minnesota (170)
Missouri (47)
Montana (14)
Nebraska (10)
Nevada (33)
New Hampshire (39)
New Jersey (1087)
New Mexico (11)
New York (1092)
North Carolina (491)
North Dakota (4)
Northern California (1565)
Ohio (93)
Oklahoma (7)
Oregon (15)
Pennsylvania (616)
Puerto Rico (5)
Rhode Island (12)
South America (423)
South Carolina (10)
Southern California (1274)
Tennessee (30)
Texas (645)
United States (12660)
Utah (103)
Virginia (71)
Washington D.C. (46)
Washington State (375)
West Virginia (2)
Wisconsin (41)
332,959 Results for "roswell park cancer institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer
November 20, 2024
·
4 min read
Business
Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI
Generate:Biomedicines and Roswell Park Comprehensive Cancer Center announced a strategic collaboration to discover and develop chimeric antigen receptor T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.
November 1, 2023
·
5 min read
BioMidwest
AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage TNBC
AIM ImmunoTech Inc. announced that Roswell Park Comprehensive Cancer Center has reported the complete topline data from its Phase 1 study evaluating Ampligen® as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer.
September 11, 2023
·
5 min read
Press Releases
Parker Institute Appoints Renowned Cancer Immunologist Dr. Ira Mellman as President of Research
April 10, 2025
·
4 min read
Press Releases
Karen Knudsen, MBA PhD, Appointed Chief Executive Officer of the Parker Institute for Cancer Immunotherapy
April 1, 2025
·
7 min read
Press Releases
HUNTSMAN CANCER INSTITUTE BREAKS GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD: EXPANDING ACCESS TO WORLD-CLASS CANCER CARE AND LIFESAVING RESEARCH TO MORE UTAH COMMUNITIES
April 11, 2025
·
8 min read
Business
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property
Northwest Biotherapeutics announced today that on June 12, 2024 it entered into an exclusive license from Roswell Park Comprehensive Cancer Center for a portfolio of dendritic cell technologies and intellectual property (IP).
June 17, 2024
·
6 min read
Press Releases
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
April 21, 2025
·
4 min read
Biotech Bay
The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators
The Parker Institute for Cancer Immunotherapy, a collaborative consortium of the world’s leading immuno-oncology experts, named its 2024 class of Early Career Researcher awardees who are poised to redefine what is possible in cancer research.
June 27, 2024
·
6 min read
BioMidwest
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a CKM Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
AIM ImmunoTech Inc. announced the presentation of positive data from research led by Roswell Park Comprehensive Cancer Center medical oncologist Shipra Gandhi, MD, evaluating Ampligen® as a component of a CKM regimen for the treatment of early-stage triple negative breast cancer.
November 14, 2022
·
6 min read
1 of 33,296
Next
